Immunotherapy in Combination with Well-Established Treatment Strategies in Pancreatic Cancer: Current Insights

References

• Kleeff J, Korc M, Apte M, et al. Pancreatic cancer. Nat Rev Dis Primers. 2016;2:16022. doi:10.1038/nrdp.2016.22
   PubMed Web of Science ®Google Scholar
• Puckett Y, Garfield K. Pancreatic Cancer. StatPearls; 2021.
   Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–2921. doi:10.1158/0008-5472.CAN-14-0155
   PubMed Web of Science ®Google Scholar
• Siegel R, Miller K, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5e29.
   Web of Science ®Google Scholar
• Reyes-Gibby CC, Chan W, Abbruzzese JL, et al. Patterns of self-reported symptoms in pancreatic cancer patients receiving chemoradiation. J Pain Symptom Manage. 2007;34(3):244–252. doi:10.1016/j.jpainsymman.2006.11.007
   PubMed Web of Science ®Google Scholar
• Löhr M. Is it possible to survive pancreatic cancer? Nat Clin Pract Gastroenterol Hepatol. 2006;3(5):236–237. doi:10.1038/ncpgasthep0469
   PubMedGoogle Scholar
• Herzberg B, Campo MJ, Gainor JF. Immune checkpoint inhibitors in non-small cell lung cancer. Oncologist. 2017;22(1):81–88. doi:10.1634/theoncologist.2016-0189
   PubMed Web of Science ®Google Scholar
• Schizas D, Charalampakis N, Kole C, et al. Immunotherapy for pancreatic cancer: a 2020 update. Cancer Treat Rev. 2020;86:102016. doi:10.1016/j.ctrv.2020.102016
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723. doi:10.1056/NEJMoa1003466
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. Decade in review-cancer immunotherapy: entering the mainstream of cancer treatment. Nat Rev Clin Oncol. 2014;11(11):630–632. doi:10.1038/nrclinonc.2014.174
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264. doi:10.1038/nrc3239
   PubMed Web of Science ®Google Scholar
• Disis ML. Mechanism of action of immunotherapy. Semin Oncol. 2014;41:S3–S13. doi:10.1053/j.seminoncol.2014.09.004
   PubMed Web of Science ®Google Scholar
• Nomi T, Sho M, Akahori T, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res. 2007;13(7):2151–2157. doi:10.1158/1078-0432.CCR-06-2746
   PubMed Web of Science ®Google Scholar
• Zhang Y, Velez-Delgado A, Mathew E, et al. Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer. Gut. 2017;66(1):124–136. doi:10.1136/gutjnl-2016-312078
   PubMed Web of Science ®Google Scholar
• Farren MR, Mace TA, Geyer S, et al. Systemic immune activity predicts overall survival in treatment-naive patients with metastatic pancreatic cancer. Clin Cancer Res. 2016;22(10):2565–2574. doi:10.1158/1078-0432.CCR-15-1732
   PubMed Web of Science ®Google Scholar
• Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14(4):847–856. doi:10.1158/1535-7163.MCT-14-0983
   PubMed Web of Science ®Google Scholar
• Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer. 2008;8(2):108–120. doi:10.1038/nrc2326
   PubMed Web of Science ®Google Scholar
• Aranda F, Vacchelli E, Eggermont A, et al. Trial watch: peptide vaccines in cancer therapy. Oncoimmunology. 2013;2(12):e26621. doi:10.4161/onci.26621
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Martins I, Eggermont A, et al. Trial watch: peptide vaccines in cancer therapy. Oncoimmunology. 2012;1(9):1557–1576. doi:10.4161/onci.22428
   PubMed Web of Science ®Google Scholar
• Akce M, Zaidi MY, Waller EK, El-Rayes BF, Lesinski GB. The potential of CAR T cell therapy in pancreatic cancer. Front Immunol. 2018;9:2166. doi:10.3389/fimmu.2018.02166
   PubMed Web of Science ®Google Scholar
• Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol. 2014;32:659–702. doi:10.1146/annurev-immunol-032713-120145
   PubMed Web of Science ®Google Scholar
• Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother. 2005;49(11):4721–4732. doi:10.1128/AAC.49.11.4721-4732.2005
   PubMed Web of Science ®Google Scholar
• Covino DA, Sabbatucci M, Fantuzzi L. The CCL2/CCR2 axis in the pathogenesis of HIV-1 infection: a new cellular target for therapy? Curr Drug Targets. 2016;17(1):76–110. doi:10.2174/138945011701151217110917
   PubMed Web of Science ®Google Scholar
• Fei L, Ren X, Yu H, Zhan Y. Targeting the CCL2/CCR2 axis in cancer immunotherapy: one stone, three birds? Front Immunol. 2021;12:771210. doi:10.3389/fimmu.2021.771210
   PubMed Web of Science ®Google Scholar
• Royal RE, Levy C, Turner K, et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010;33(8):828–833. doi:10.1097/CJI.0b013e3181eec14c
   PubMed Web of Science ®Google Scholar
• AstraZeneca. Study of tremelimumab in patients with advanced solid tumors. Available from: https://clinicaltrials.gov/show/NCT02527434. Accessed May 3, 2021.
   Google Scholar
• Klaiber U, Hackert T, Neoptolemos JP. Adjuvant treatment for pancreatic cancer. Transl Gastroenterol Hepatol. 2019;4:27. doi:10.21037/tgh.2019.04.04
   PubMed Web of Science ®Google Scholar
• Okusaka T, Nakamura M, Yoshida M, et al. Clinical practice guidelines for pancreatic cancer 2019 from the Japan Pancreas Society: a synopsis. Pancreas. 2020;49(3):326–335. doi:10.1097/MPA.0000000000001513
   PubMed Web of Science ®Google Scholar
• Kayahara M, Funaki K, Tajima H, et al. Surgical implication of micrometastasis for pancreatic cancer. Pancreas. 2010;39(6):884–888. doi:10.1097/MPA.0b013e3181ce6daa
   PubMed Web of Science ®Google Scholar
• Trimble EL, Ungerleider RS, Abrams JA, et al. Neoadjuvant therapy in cancer treatment. Cancer. 1993;72(11 Suppl):3515–3524.
   PubMed Web of Science ®Google Scholar
• Byrne KT, Vonderheide RH. CD40 stimulation obviates innate sensors and drives T cell immunity in cancer. Cell Rep. 2016;15(12):2719–2732. doi:10.1016/j.celrep.2016.05.058
   PubMed Web of Science ®Google Scholar
• Amin S, Baine M, Meza J, Lin C. The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: a retrospective analysis. BMC Cancer. 2020;20(1):538. doi:10.1186/s12885-020-07016-8
   PubMed Web of Science ®Google Scholar
• Teng F, Mu D, Meng X, et al. Tumor infiltrating lymphocytes (TILs) before and after neoadjuvant chemoradiotherapy and its clinical utility for rectal cancer. Am J Cancer Res. 2015;5(6):2064–2074.
   PubMed Web of Science ®Google Scholar
• Ogawa K, Hirai M, Katsube T, et al. Suppression of cellular immunity by surgical stress. Surgery. 2000;127(3):329–336. doi:10.1067/msy.2000.103498
   PubMed Web of Science ®Google Scholar
• Hogan BV, Peter MB, Shenoy HG, Horgan K, Hughes TA. Surgery induced immunosuppression. Surgeon. 2011;9(1):38–43. doi:10.1016/j.surge.2010.07.011
   PubMed Web of Science ®Google Scholar
• Rahma OE, Katz MHG, Wolpin BM, et al. Randomized multicenter phase Ib/II study of neoadjuvant chemoradiation therapy (CRT) alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic cancer. J Clin Oncol. 2021;39(15_suppl):4128. doi:10.1200/JCO.2021.39.15_suppl.4128
   Web of Science ®Google Scholar
• University Z. Combination of anti-PD-1 antibody and chemotherapy in pancreatic cancer; 2019. Available from: https://clinicaltrials.gov/show/NCT03983057. Accessed February 14, 2022.
   Google Scholar
• Zhou X, Hou W, Gao L, Shui L, Yi C, Zhu H. Synergies of antiangiogenic therapy and immune checkpoint blockade in renal cell carcinoma: from theoretical background to clinical reality. Front Oncol. 2020;10:1321. doi:10.3389/fonc.2020.01321
   PubMed Web of Science ®Google Scholar
• Murphy JM, Rodriguez YAR, Jeong K, Ahn EE, Lim SS. Targeting focal adhesion kinase in cancer cells and the tumor microenvironment. Exp Mol Med. 2020;52(6):877–886. doi:10.1038/s12276-020-0447-4
   PubMed Web of Science ®Google Scholar
• Hopkins SK, Sharp M, Corp D, Verastem I. Study of pembrolizumab with or without defactinib following chemotherapy as a neoadjuvant and adjuvant treatment for resectable pancreatic ductal adenocarcinoma. Available from: https://clinicaltrials.gov/show/NCT03727880. Accessed March 26, 2021.
   Google Scholar
• Saxena M, van der Burg SH, Melief CJM, Bhardwaj N. Therapeutic cancer vaccines. Nat Rev Cancer. 2021;21(6):360–378. doi:10.1038/s41568-021-00346-0
   PubMed Web of Science ®Google Scholar
• Rosenberg A, Mahalingam D. Immunotherapy in pancreatic adenocarcinoma-overcoming barriers to response. J Gastrointest Oncol. 2018;9(1):143–159. doi:10.21037/jgo.2018.01.13
   PubMed Web of Science ®Google Scholar
• Hopkins SK, Institute NC. Vaccine therapy with or without cyclophosphamide in treating patients undergoing chemotherapy and radiation therapy for stage I or stage II pancreatic cancer that can be removed by surgery. Available from: https://clinicaltrials.gov/show/NCT00727441. Accessed February 25, 2020.
   Google Scholar
• Lee V, Ding D, Rodriguez C, et al. A phase 2 study of cyclophosphamide (CY), GVAX, pembrolizumab (Pembro), and stereotactic body radiation (SBRT) in patients (pts) with locally advanced pancreas cancer (LAPC). J Clin Oncol. 2021;39(suppl 15):abstr 4134. doi:10.1200/JCO.2021.39.15_suppl.4134
   Web of Science ®Google Scholar
• Lee V, Rodriguez C, Shupe EM, et al. Phase II study of GM-CSF secreting allogeneic pancreatic cancer vaccine (GVAX) with PD-1 blockade antibody and stereotactic body radiation therapy (SBRT) for locally advanced pancreas cancer (LAPC). J Clin Oncol. 2017;35(15_suppl):TPS4154. doi:10.1200/JCO.2017.35.15_suppl.TPS4154
   Web of Science ®Google Scholar
• Hopkins SK, Sharp M, Corp D, Lilly E. Pilot study with CY, pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in patients with borderline resectable adenocarcinoma of the pancreas. Available from: https://clinicaltrials.gov/show/NCT03153410. Accessed March 30, 2021.
   Google Scholar
• Institute NC, Center NIoHC. Immune checkpoint inhibitor M7824 and the immunocytokine M9241 in combination with stereotactic body radiation therapy (SBRT) in adults with advanced pancreas cancer. Available from: https://clinicaltrials.gov/show/NCT04327986. Accessed June 18, 2021.
   Google Scholar
• Corporation NG, Pharma L. Immunotherapy and SBRT study in borderline resectable pancreatic cancer. Available from: https://clinicaltrials.gov/show/NCT02405585. Accessed May 28, 2020.
   Google Scholar
• Corporation NG, Pharma L. Immunotherapy study in borderline resectable or locally advanced unresectable pancreatic cancer. Available from: https://clinicaltrials.gov/show/NCT01836432. Accessed May 28, 2020.
   Google Scholar
• Hopkins SK, Institute NC, Squibb B-M. Neoadjuvant/adjuvant GVAX pancreas vaccine (with CY) with or without nivolumab and urelumab trial for surgically resectable pancreatic cancer. Available from: https://clinicaltrials.gov/show/NCT02451982. Accessed February 14, 2022.
   Google Scholar
• Center JCC, Squibb B-M, Ltd. N. Nivolumab in combination with chemotherapy before surgery in treating patients with borderline resectable pancreatic cancer. Available from: https://clinicaltrials.gov/show/NCT03970252. Accessed May 14, 2021.
   Google Scholar
• Candel Therapeutics I, University OS. Neoadjuvant GMCI plus chemoradiation for advanced non-metastatic pancreatic adenocarcinoma. Available from: https://clinicaltrials.gov/show/NCT02446093. Accessed December 7, 2020.
   Google Scholar
• Hopkins SK, Squibb BM. Trial of neoadjuvant and adjuvant nivolumab and BMS-813160 with or without GVAX for locally advanced pancreatic ductal adenocarcinomas. Available from: https://clinicaltrials.gov/show/NCT03767582. Accessed March 26, 2021.
   Google Scholar
• ChemoCentryx. Phase 1b study of CCX872-B in patients with pancreatic adenocarcinoma. Available from: https://clinicaltrials.gov/show/NCT02345408. Accessed August 16, 2019.
   Google Scholar
• Katz A, Rochester UO. Pre-operative stereotactic body radiation therapy for pancreatic adenocarcinoma with or without CCX872-B. Available from: https://clinicaltrials.gov/show/NCT03778879. Accessed July 19, 2019.
   Google Scholar
• Medicine WUSo, Institute NC. FOLFIRINOX plus PF-04136309 in patients with borderline resectable and locally advanced pancreatic adenocarcinoma. Available from: https://clinicaltrials.gov/show/NCT01413022. Accessed September 19, 2016.
   Google Scholar
• Nywening TM, Wang-Gillam A, Sanford DE, et al. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol. 2016;17(5):651–662. doi:10.1016/S1470-2045(16)00078-4
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Kleeff J, Michl P, Costello E, Greenhalf W, Palmer DH. Therapeutic developments in pancreatic cancer: current and future perspectives. Nat Rev Gastroenterol Hepatol. 2018;15(6):333–348. doi:10.1038/s41575-018-0005-x
   PubMed Web of Science ®Google Scholar
• Lutz E, Yeo CJ, Lillemoe KD, et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A phase II trial of safety, efficacy, and immune activation. Ann Surg. 2011;253(2):328–335. doi:10.1097/SLA.0b013e3181fd271c
   PubMed Web of Science ®Google Scholar
• Jaffee EM, Hruban RH, Biedrzycki B, et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol. 2001;19(1):145–156. doi:10.1200/JCO.2001.19.1.145
   PubMed Web of Science ®Google Scholar
• Hardacre JM, Mulcahy M, Small W, et al. Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study. J Gastrointest Surg. 2013;17(1):94–100;discussion p 100–1. doi:10.1007/s11605-012-2064-6
   Web of Science ®Google Scholar
• Hewitt DB, Nissen N, Hatoum H, et al. A phase 3 randomized clinical trial of chemotherapy with or without algenpantucel-L (hyperacute-pancreas) immunotherapy in subjects with borderline resectable or locally advanced unresectable pancreatic cancer. Ann Surg. 2020;271:1072–1079. doi:10.1097/SLA.0000000000004669
   PubMed Web of Science ®Google Scholar
• McCormick KA, Coveler AL, Rossi GR, Vahanian NN, Link C, Chiorean EG. Pancreatic cancer: update on immunotherapies and algenpantucel-L. Hum Vaccin Immunother. 2016;12(3):563–575. doi:10.1080/21645515.2015.1093264
   PubMed Web of Science ®Google Scholar
• Zeitouni D, Pylayeva-Gupta Y, Der CJ, Bryant KL. KRAS mutant pancreatic cancer: no lone path to an effective treatment. Cancers (Basel). 2016;8(4):45. doi:10.3390/cancers8040045
   PubMed Web of Science ®Google Scholar
• Gjertsen MK, Buanes T, Rosseland AR, et al. Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer. 2001;92(3):441–450. doi:10.1002/ijc.1205
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Chapman PB, Feilchenfeldt J, et al. Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine. Am J Clin Oncol. 2011;34(3):321–325. doi:10.1097/COC.0b013e3181e84b1f
   PubMed Web of Science ®Google Scholar
• ASA T. Antigen-specific cancer immunotherapy (TG01) and gemcitabine as adjuvant therapy in resected pancreatic cancer. Available from: https://clinicaltrials.gov/show/NCT02261714. Accessed May 14, 2020.
   Google Scholar
• Muscarella P, Wilfong LS, Ross SB, et al. A randomized, placebo-controlled, double blind, multicenter phase II adjuvant trial of the efficacy, immunogenicity, and safety of GI-4000 plus gem versus gem alone in patients with resected pancreas cancer with activating RAS mutations/survival and immunology analysis of the R1 subgroup. J Clin Oncol. 2012;30(15_suppl):e14501. doi:10.1200/jco.2012.30.15_suppl.e14501
   Google Scholar
• Miyazawa M, Katsuda M, Maguchi H, et al. Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients. Int J Cancer. 2017;140(4):973–982. doi:10.1002/ijc.30510
   PubMed Web of Science ®Google Scholar
• Hopkins SK, Squibb BM. Trial of neoadjuvant and adjuvant nivolumab and BMS-813160 with or without GVAX for locally advanced pancreatic ductal adenocarcinomas. Available from: https://clinicaltrials.gov/show/NCT03767582. Accessed August 20, 2021.
   Google Scholar
• Medicine WUSo, Squibb B-M, Hospital TFfB-J, Health NIo, Institute NC. BMS-813160 with nivolumab and gemcitabine and Nab-paclitaxel in borderline resectable and locally advanced pancreatic ductal adenocarcinoma (PDAC). Available from: https://clinicaltrials.gov/show/NCT03496662. Accessed November 3, 2021.
   Google Scholar
• University N, Center RHLC. Ipilimumab and gemcitabine hydrochloride in treating patients with stage III-IV or recurrent pancreatic cancer that cannot be removed by surgery. Available from: https://clinicaltrials.gov/show/NCT01473940. Accessed March 6, 2020.
   Google Scholar
• Squibb BM. An investigational study of immunotherapy combinations with chemotherapy in patients with gastric or gastroesophageal junction (GEJ) cancers. Available from: https://clinicaltrials.gov/show/NCT03662659. Accessed August 27, 2020.
   Google Scholar
• A study of nivolumab by itself or nivolumab combined with ipilimumab in patients with advanced or metastatic solid tumors. Available from: https://clinicaltrials.gov/show/NCT01928394. Accessed February 14, 2022.
   Google Scholar
• Le DT, Lutz E, Uram JN, et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother. 2013;36(7):382–389. doi:10.1097/CJI.0b013e31829fb7a2
   PubMed Web of Science ®Google Scholar
• Hopkins SKCCCaJ, Squibb B-M, Cancer SUT, Aduro Biotech I, Research AAfC, Foundation L. GVAX pancreas vaccine (with CY) and CRS-207 with or without nivolumab. Available from: https://clinicaltrials.gov/show/NCT02243371. Accessed April 6, 2021.
   Google Scholar
• Aglietta M, Barone C, Sawyer MB, et al. A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer. Ann Oncol. 2014;25(9):1750–1755. doi:10.1093/annonc/mdu205
   PubMed Web of Science ®Google Scholar
• Weiss GJ, Blaydorn L, Beck J, et al. Correction to: phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma. Invest New Drugs. 2019;37:797. doi:10.1007/s10637-019-00763-x
   PubMed Web of Science ®Google Scholar
• Weiss GJ, Blaydorn L, Beck J, et al. Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma. Invest New Drugs. 2018;36(1):96–102. doi:10.1007/s10637-017-0525-1
   PubMed Web of Science ®Google Scholar
• University Z. Combination of anti-PD-1 antibody and chemotherapy in metastatic pancreatic cancer. Available from: https://clinicaltrials.gov/show/NCT03977272. Accessed December 11, 2019.
   Google Scholar
• Cheng K, Lv WR, Li X, Tian B, Cao D. Toripalimab with nab-paclitaxel/gemcitabine as first-line treatment for advanced pancreatic adenocarcinoma: updated results of a single-arm, open-label, phase Ib/II clinical study. J Clin Oncol. 2021;39(suppl15):abstr e16213. doi:10.1200/JCO.2021.39.15_suppl.e16213
   Web of Science ®Google Scholar
• Zhu H, Sun X, Pan X, Wu P, Chen J. Sindilimab combined with nab-paclitaxel plus gemcitabine as first-line treatment for patients with advanced pancreatic cancer. J Clin Oncol. 2021;39(suppl 15):abstr e16257. doi:10.1200/JCO.2021.39.15_suppl.e16257
   Web of Science ®Google Scholar
• Suurs FV, Lub-de Hooge MN, de Vries EGE, de Groot DJA. A review of bispecific antibodies and antibody constructs in oncology and clinical challenges. Pharmacol Ther. 2019;201:103–119. doi:10.1016/j.pharmthera.2019.04.006
   PubMed Web of Science ®Google Scholar
• Jin D, Guo S, Zhang Y, et al. Efficacy and safety of KN046 plus nab-paclitaxel/gemcitabine as first-line treatment for unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC). J Clin Oncol. 2021;39(suppl15):abstr 4138. doi:10.1200/JCO.2021.39.15_suppl.4138
   Web of Science ®Google Scholar
• Xie J, Chen L, Hua Y, Ii H, Meng Z. 982P - A phase II study of SHR-1701 plus famitinib for patients with previously treated advanced pancreatic cancer or biliary tract cancer. Ann Oncol. 2021;32(suppl_5):S829–S866. doi:10.1016/annonc/annonc705
   PubMedGoogle Scholar
• Berraondo P, Sanmamed MF, Ochoa MC, et al. Cytokines in clinical cancer immunotherapy. Br J Cancer. 2019;120(1):6–15. doi:10.1038/s41416-018-0328-y
   PubMed Web of Science ®Google Scholar
• Grell P, Lin CC, Milella M, et al. Phase II study of the anti-TGF-β monoclonal antibody (mAb) NIS793 with and without the PD-1 inhibitor spartalizumab in combination with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC). J Clin Oncol. 2021;39(suppl15):abstr TPS4173.
   Google Scholar
• Awada AH, Zematis M, Ochsenreither S, et al. 538P - nadunolimab (CAN04), a first-in-class monoclonal antibody against IL1RAP, in combination with chemotherapy in subjects with pancreatic cancer (PDAC) and non-small cell lung cancer (NSCLC). Ann Oncol. 2021;32(suppl_5):S583–S620. doi:10.1016/annonc/annonc699
   Google Scholar
• Hecht JR, Lonardi S, Bendell JC, et al. Randomized phase III study of FOLFOX alone and with pegilodecakin as second-line therapy in patients with metastatic pancreatic cancer (SEQUOIA). J Clin Oncol. 2020;38(4_suppl):637. doi:10.1200/JCO.2020.38.4_suppl.637
   Google Scholar
• Whiting C, Lutz E, Nair N, et al. Phase II, randomized study of GVAX pancreas and CRS-207 immunotherapy in patients with metastatic pancreatic cancer: clinical update on long term survival and biomarker correlates to overall survival. J Clin Oncol. 2015;33(3_suppl):261. doi:10.1200/jco.2015.33.3_suppl.261
   Web of Science ®Google Scholar
• Le DT, Picozzi VJ, Ko AH, et al. Results from a phase IIb, randomized, multicenter study of GVAX pancreas and CRS-207 compared with chemotherapy in adults with previously treated metastatic pancreatic adenocarcinoma (ECLIPSE study). Clin Cancer Res. 2019;25:5493–5502. doi:10.1158/1078-0432.CCR-18-2992
   PubMed Web of Science ®Google Scholar
• Asahara S, Takeda K, Yamao K, Maguchi H, Yamaue H. Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer. J Transl Med. 2013;11:291. doi:10.1186/1479-5876-11-291
   PubMed Web of Science ®Google Scholar
• Suzuki N, Hazama S, Iguchi H, et al. Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: venus-PC study. Cancer Sci. 2017;108(1):73–80. doi:10.1111/cas.13113
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Kim-Schulze S, Manson K, et al. Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer. J Transl Med. 2007;5:60. doi:10.1186/1479-5876-5-60
   PubMed Web of Science ®Google Scholar
• Middleton G, Silcocks P, Cox T, et al. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. Lancet Oncol. 2014;15(8):829–840. doi:10.1016/S1470-2045(14)70236-0
   PubMed Web of Science ®Google Scholar
• Jiang N, Qiao G, Wang X, et al. Dendritic cell/cytokine-induced killer cell immunotherapy combined with S-1 in patients with advanced pancreatic cancer: a prospective study. Clin Cancer Res. 2017;23(17):5066–5073. doi:10.1158/1078-0432.CCR-17-0492
   PubMed Web of Science ®Google Scholar
• Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019;94(S1):S3–S9. doi:10.1002/ajh.25418
   PubMed Web of Science ®Google Scholar
• Raj D, Yang MH, Rodgers D, et al. Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma. Gut. 2019;68(6):1052–1064. doi:10.1136/gutjnl-2018-316595
   PubMed Web of Science ®Google Scholar
• Chi J, Patel R, Rehman H, Goyal S, Saif MW. Recent advances in immunotherapy for pancreatic cancer. J Cancer Metast Treat. 2020;6:43. doi:10.20517/2394-4722.2020.90
   Google Scholar
• Beatty GL, O’Hara MH, Lacey SF, et al. Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial. Gastroenterology. 2018;155(1):29–32. doi:10.1053/j.gastro.2018.03.029
   PubMed Web of Science ®Google Scholar
• O’Hara MH, O’Reilly EM, Wolff RA. Gemcitabine (Gem) and nab-paclitaxel (NP) ± nivolumab (nivo) ± CD40 agonistic monoclonal antibody APX005M (Sotigalimab), in patients (Pts) with untreated metastatic pancreatic adenocarcinoma (mPDAC): phase (Ph) 2 final results. J Clin Oncol. 2021;39(suppl15):abstr 4019. doi:10.1200/JCO.2021.39.15_suppl.4019
   Web of Science ®Google Scholar
• Dubreuil P, Letard S, Ciufolini M, et al. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS One. 2009;4(9):e7258. doi:10.1371/journal.pone.0007258
   PubMed Web of Science ®Google Scholar
• Ezenfis J, Hermine O, Group AS. Masitinib plus gemcitabine as first-line treatment of pancreatic cancer with pain: results from phase 3 study AB12005. J Clin Oncol. 2021;39(15_suppl):4018. doi:10.1200/JCO.2021.39.15_suppl.4018
   Web of Science ®Google Scholar
• Cassier PA, Garin G, Eberst L, et al. MEDIPLEX: a phase 1 study of durvalumab (D) combined with pexidartinib (P) in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC). J Clin Oncol. 2019;37(15_suppl):2579. doi:10.1200/JCO.2019.37.15_suppl.2579
   Web of Science ®Google Scholar
• Wang Y, Deng W, Li N, et al. Combining immunotherapy and radiotherapy for cancer treatment: current challenges and future directions. Front Pharmacol. 2018;9:185. doi:10.3389/fphar.2018.00185
   PubMed Web of Science ®Google Scholar
• Seery TE, Nangia CS, Sender LS, Reddy SK, Soon-Shiong P. Trial in progress: open-label, randomized, comparative phase 2/3 study of combination immunotherapy plus standard-of-care chemotherapy and SBRT versus standard-of-care chemotherapy for the treatment of locally advanced or metastatic pancreatic cancer. J Clin Oncol. 2021;39(suppl15):abstr TPS4174. doi:10.1200/JCO.2021.39.15_suppl.TPS4174
   Web of Science ®Google Scholar
• Li Z, Li Q, Ma Z, et al. Camrelizumab combined with ablation and chemotherapy for pancreatic cancer with liver metastases: a single-arm, phase II, prospective clinical study. J Clin Oncol. 2021;39(suppl15):abstr TPS4169. doi:10.1200/JCO.2021.39.15_suppl.TPS4169
   Web of Science ®Google Scholar
• Neesse A, Algul H, Tuveson DA, Gress TM. Stromal biology and therapy in pancreatic cancer: a changing paradigm. Gut. 2015;64(9):1476–1484. doi:10.1136/gutjnl-2015-309304
   PubMed Web of Science ®Google Scholar
• Torphy RJ, Zhu Y, Schulick RD. Immunotherapy for pancreatic cancer: barriers and breakthroughs. Ann Gastroenterol Surg. 2018;2(4):274–281. doi:10.1002/ags3.12176
   PubMed Web of Science ®Google Scholar
• Murakami T, Hiroshima Y, Matsuyama R, Homma Y, Hoffman RM, Endo I. Role of the tumor microenvironment in pancreatic cancer. Ann Gastroenterol Surg. 2019;3(2):130–137. doi:10.1002/ags3.12225
   PubMed Web of Science ®Google Scholar
• Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008;8(7):523–532. doi:10.1038/nri2343
   PubMed Web of Science ®Google Scholar
• Walker LS. Treg and CTLA-4: two intertwining pathways to immune tolerance. J Autoimmun. 2013;45:49–57. doi:10.1016/j.jaut.2013.06.006
   PubMed Web of Science ®Google Scholar
• Bailey P, Chang DK, Forget MA, et al. Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma. Sci Rep. 2016;6:35848. doi:10.1038/srep35848
   PubMed Web of Science ®Google Scholar
• Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41(1):49–61. doi:10.1016/j.immuni.2014.06.010
   PubMed Web of Science ®Google Scholar
• Allavena P, Piemonti L, Longoni D, et al. IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur J Immunol. 1998;28(1):359–369. doi:10.1002/(SICI)1521-4141(199801)28:01<359::AID-IMMU359>3.0.CO;2-4
   PubMed Web of Science ®Google Scholar
• Blazquez JL, Benyamine A, Pasero C, Olive D. New insights into the regulation of gammadelta T cells by BTN3A and other BTN/BTNL in tumor immunity. Front Immunol. 2018;9:1601. doi:10.3389/fimmu.2018.01601
   PubMed Web of Science ®Google Scholar
• Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–413. doi:10.1126/science.aan6733
   PubMed Web of Science ®Google Scholar
• Yamamoto H, Imai K. Microsatellite instability: an update. Arch Toxicol. 2015;89(6):899–921. doi:10.1007/s00204-015-1474-0
   PubMed Web of Science ®Google Scholar
• Lower SS, McGurk MP, Clark AG, Barbash DA. Satellite DNA evolution: old ideas, new approaches. Curr Opin Genet Dev. 2018;49:70–78. doi:10.1016/j.gde.2018.03.003
   PubMed Web of Science ®Google Scholar
• Veigl ML, Kasturi L, Olechnowicz J, et al. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci U S A. 1998;95:8698–8702. doi:10.1073/pnas.95.15.8698
   PubMed Web of Science ®Google Scholar
• Hu ZI, Shia J, Stadler ZK, et al. Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations. Clin Cancer Res. 2018;24(6):1326–1336. doi:10.1158/1078-0432.CCR-17-3099
   PubMed Web of Science ®Google Scholar
• Nakata B, Wang YQ, Yashiro M, et al. Prognostic value of microsatellite instability in resectable pancreatic cancer. Clin Cancer Res. 2002;8(8):2536–2540.
   PubMed Web of Science ®Google Scholar
• Fraune C, Burandt E, Simon R, et al. MMR deficiency is homogeneous in pancreatic carcinoma and associated with high density of cd8-positive lymphocytes. Ann Surg Oncol. 2020;27:3997–4006. doi:10.1245/s10434-020-08209-y
   PubMed Web of Science ®Google Scholar
• Yamamoto H, Itoh F, Nakamura H, et al. Genetic and clinical features of human pancreatic ductal adenocarcinomas with widespread microsatellite instability. Cancer Res. 2001;61(7):3139–3144.
   PubMed Web of Science ®Google Scholar
• Eatrides JM, Coppola D, Diffalha SA, Kim RD, Springett GM, Mahipal A. Microsatellite instability in pancreatic cancer. J Clin Oncol. 2016;34(15_suppl):e15753. doi:10.1200/JCO.2016.34.15_suppl.e15753
   Web of Science ®Google Scholar
• Wang L, Ma Q, Chen X, Guo K, Li J, Zhang M. Clinical significance of B7-H1 and B7-1 expressions in pancreatic carcinoma. World J Surg. 2010;34(5):1059–1065. doi:10.1007/s00268-010-0448-x
   PubMed Web of Science ®Google Scholar
• Chen Y, Sun J, Zhao H, et al. The coexpression and clinical significance of costimulatory molecules B7-H1, B7-H3, and B7-H4 in human pancreatic cancer. Onco Targets Ther. 2014;7:1465–1472. doi:10.2147/OTT.S66809
   PubMed Web of Science ®Google Scholar
• Loos M, Giese NA, Kleeff J, et al. Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer. Cancer Lett. 2008;268(1):98–109. doi:10.1016/j.canlet.2008.03.056
   PubMed Web of Science ®Google Scholar
• Geng L, Huang D, Liu J, et al. B7-H1 up-regulated expression in human pancreatic carcinoma tissue associates with tumor progression. J Cancer Res Clin Oncol. 2008;134(9):1021–1027. doi:10.1007/s00432-008-0364-8
   PubMed Web of Science ®Google Scholar
• Birnbaum DJ, Finetti P, Lopresti A, et al. Prognostic value of PDL1 expression in pancreatic cancer. Oncotarget. 2016;7(44):71198–71210. doi:10.18632/oncotarget.11685
   PubMedGoogle Scholar
• Gao HL, Liu L, Qi ZH, et al. The clinicopathological and prognostic significance of PD-L1 expression in pancreatic cancer: a meta-analysis. Hepatobiliary Pancreat Dis Int. 2018;17(2):95–100. doi:10.1016/j.hbpd.2018.03.007
   PubMed Web of Science ®Google Scholar
• Salem ME, Puccini A, Grothey A, et al. Landscape of tumor mutation load, mismatch repair deficiency, and PD-L1 expression in a large patient cohort of gastrointestinal cancers. Mol Cancer Res. 2018;16(5):805–812. doi:10.1158/1541-7786.MCR-17-0735
   PubMed Web of Science ®Google Scholar
• Kim ST, Klempner SJ, Park SH, et al. Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy. Oncotarget. 2017;8(44):77415–77423. doi:10.18632/oncotarget.20492
   PubMedGoogle Scholar
• Champiat S, Ferte C, Lebel-Binay S, Eggermont A, Soria JC. Exomics and immunogenics: bridging mutational load and immune checkpoints efficacy. Oncoimmunology. 2014;3(1):e27817. doi:10.4161/onci.27817
   PubMed Web of Science ®Google Scholar
• Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair–deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1–10. doi:10.1200/jco.19.02105
   PubMed Web of Science ®Google Scholar
• Pokataev I, Fedyanin M, Polyanskaya E, et al. Efficacy of platinum-based chemotherapy and prognosis of patients with pancreatic cancer with homologous recombination deficiency: comparative analysis of published clinical studies. ESMO Open. 2020;5(1):e000578. doi:10.1136/esmoopen-2019-000578
   PubMed Web of Science ®Google Scholar
• Nguyen L, W. M. Martens J, Van Hoeck A, Cuppen E. Pan-cancer landscape of homologous recombination deficiency. Nat Commun. 2020;11(1):5584. doi:10.1038/s41467-020-19406-4
   PubMed Web of Science ®Google Scholar
• Casolino R, Paiella S, Azzolina D, et al. Homologous recombination deficiency in pancreatic cancer: a systematic review and prevalence meta-analysis. J Clin Oncol. 2021;39(23):2617–2631. doi:10.1200/jco.20.03238
   PubMed Web of Science ®Google Scholar
• Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381(4):317–327. doi:10.1056/NEJMoa1903387
   PubMed Web of Science ®Google Scholar
• Reiss KA, Mick R, O’Hara MH, et al. Phase II study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2. J Clin Oncol. 2021;39(22):2497–2505. doi:10.1200/JCO.21.00003
   PubMed Web of Science ®Google Scholar
• Vikas P, Borcherding N, Chennamadhavuni A, Garje R. Therapeutic potential of combining PARP inhibitor and immunotherapy in solid tumors. Front Oncol. 2020;10:570. doi:10.3389/fonc.2020.00570
   PubMed Web of Science ®Google Scholar
• Shan C, Li X, Zhang J. Progress of immune checkpoint LAG-3 in immunotherapy. Oncol Lett. 2020;20(5):207. doi:10.3892/ol.2020.12070
   PubMed Web of Science ®Google Scholar
• Seeber A, Kocher F, Pircher A, et al. High CXCR4 expression in pancreatic ductal adenocarcinoma as characterized by an inflammatory tumor phenotype with potential implications for an immunotherapeutic approach. J Clin Oncol. 2021;39(suppl15):abstr 4021. doi:10.1200/JCO.2021.39.15_suppl.4021
   Web of Science ®Google Scholar
• Seifert L, Plesca I, Muller L, et al. LAG-3-expressing tumor-infiltrating t cells are associated with reduced disease-free survival in pancreatic cancer. Cancers (Basel). 2021;13(6):1297. doi:10.3390/cancers13061297
   PubMed Web of Science ®Google Scholar
• Freed-Pastor WA, Lambert LJ, Ely ZA, et al. The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer. Cancer Cell. 2021;39:1342–1360.e14. doi:10.1016/j.ccell.2021.07.007
   PubMed Web of Science ®Google Scholar
• Popp FC, Capino I, Bartels J, et al. Expression of immune checkpoint regulators IDO, Vista, LAG3, and TIM3 in resected pancreatic ductal adenocarcinoma. Cancers (Basel). 2021;13(11):2689. doi:10.3390/cancers13112689
   PubMed Web of Science ®Google Scholar
• Group G-MOC, Immunotherapeutics O, Squibb B-M. Maintenance therapy with OSE2101 vaccine alone or in combination with nivolumab, or FOLFIRI after induction therapy with FOLFIRINOX in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma. Available from: https://clinicaltrials.gov/show/NCT03806309. Accessed February 12, 2020.
   Google Scholar
• Limited K, Sanofi. Safety and efficacy of KY1044 and atezolizumab in advanced cancer; 2019. Available from: https://clinicaltrials.gov/show/NCT03829501. Accessed February 14, 2022.
   Google Scholar
• Mehrotra S, Britten CD, Chin S, et al. Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer. J Hematol Oncol. 2017;10(1):82. doi:10.1186/s13045-017-0459-2
   PubMed Web of Science ®Google Scholar
• Morphotek. An efficacy study of MORAb-009 in subjects with pancreatic cancer. Available from: https://clinicaltrials.gov/show/NCT00570713. Accessed September 9, 2015.
   Google Scholar
• Clinic M, Institute NC. Sonidegib and pembrolizumab in treating patients with advanced solid tumors. Available from: https://clinicaltrials.gov/show/NCT04007744. Accessed January 15, 2021.
   Google Scholar
• Berard CL, Sharp M, Corp D, Sa DI. Pembrolizumab in combination with debio 1143 in pancreatic and colorectal advanced/metastatic adenocarcinoma. Available from: https://clinicaltrials.gov/show/NCT03871959. Accessed May 10, 2021.
   Google Scholar
• Xencor I, Research IC. A study of XmAb®22841 monotherapy & in combination w/ pembrolizumab in subjects w/ selected advanced solid tumors. Available from: https://clinicaltrials.gov/show/NCT03849469. Accessed May 5, 2021.
   Google Scholar
• Hospital MG, Squibb B-M. Nivolumab and ipilimumab and radiation therapy in MSS and MSI high colorectal and pancreatic cancer. Available from: https://clinicaltrials.gov/show/NCT03104439. Accessed March 25, 2021.
   Google Scholar
• Therapeutics F. FT500 as monotherapy and in combination with immune checkpoint inhibitors in subjects with advanced solid tumors. Available from: https://clinicaltrials.gov/show/NCT03841110. Accessed February 14, 2022.
   Google Scholar
• Lilly and Company. A study of anti-PD-L1 checkpoint antibody (LY3300054) alone and in combination in participants with advanced refractory solid tumors. Available from: https://clinicaltrials.gov/show/NCT02791334. Accessed December 17, 2020.
   Google Scholar
• Kammula U, Pittsburgh UO. Adoptive transfer of tumor infiltrating lymphocytes for advanced solid cancers. Available from: https://clinicaltrials.gov/show/NCT03935893. Accessed February 14, 2022.
   Google Scholar